Prognosis and Risks for Renal Transplant Recipients During the COVID-19 Pandemic

Renal Transplant Recipients and COVID-19


Abstract views: 59 / PDF downloads: 31

Authors

DOI:

https://doi.org/10.5281/zenodo.10654141

Keywords:

COVID-19, kidney transplant recipients, hemodialysis, prognosis

Abstract

Background: We aim to compare potential factors that may affect the prognosis of kidney transplant recipients (KTRs) and hemodialysis patients (HDPs) with the diagnosis of COVID-19.
Method: This single-center retrospective study was conducted at the University of Health Science Diskapi Yildirim Beyazit Training and Research Hospital hospital. From March 1, 2021, to September 30, 2021, 110 individuals diagnosed with COVID-19 and ≥18 years old were included in our study. The study population comprised 29 kidney transplant recipients (KTRs) and 81 hemodialysis patients (HDPs). Data were collected from the hospital’s software and included patient descriptive features, laboratory test results, medication records, demographic information, comorbidities, and clinical outcomes of COVID-19 diagnosis, such as mortality and discharge rates.
Results: A total of 110 patients (29 KTRs, 81 HDPs) were evaluated. There was no significant difference in mortality rates observed between the groups (p=0.117). Coronary artery disease (CAD) was found associated with mortality in both KTRs and HDPs (p=0.001 and p=0.021, respectively). A logistic regression analysis model identified age above 55 years as a significant mortality-related factor in HDPs (p=0.039). Pro-brain natriuretic peptide (pro-BNP) and procalcitonin levels at admission, and increase in serum creatinine, neutrophil count, lactate dehydrogenase (LDH), d-dimer, procalcitonin and urea urea during hospitalization were associated with death in KTRs (p<0.05).
Conclusion: This study highlights comparable mortality rates in KTRs and HDPs hospitalized due to COVID-19. Kidney injury (increase in creatinine, urea), presence of CAD, proBNP, D-dimer, LDH), and inflammation (increase in neutrophil count, procalcitonin) could be a predictor of mortality in KTRS with COVID-19. Despite ongoing debates on immunosuppressive medications, our findings suggest a potential role in mitigating COVID-19 severity. Additionally, age > 55 years is a strong indicator of mortality in HDPs with COVID-19.

References

Uysal E, Seğmen F, Ulubaşoğlu P, Zengin EN, Erdem D. The progress of chronic renal disease patients followed by the diagnosis of COVID-19 in ICU. J Health Sci Med / JHSM. September 2022;5(5):1443-1448. doi:10.32322/jhsm.1152051

Aziz F, Mandelbrot D, Singh T, et al. Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. Transplant Proc. 2020;52(9):2659-2662. doi:10.1016/j.transproceed.2020.07.002

Medina-Pestana J, Cristelli MP, Foresto RD, Tedesco-Silva H, Requião-Moura LR. The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients Calls for Further Action. Transplantation. 2022;106(5):908-910. doi:10.1097/TP.0000000000004086

Ozturk S, Turgutalp K, Arici M, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020;35(12):2083-2095. doi:10.1093/ndt/gfaa271

Amsei TQM, Gorayeb-Polacchini FS, Caldas HC, Fernandes-Charpiot IMM, Ferreira-Baptista MAS, Abbud-Filho M. Effect of the COVID-19 Pandemic on Kidney Transplant and on Chronic Dialysis Patients [published correction appears in Transplant Proc. 2023 Sep;55(7):1766-1767]. Transplant Proc. 2022;54(5):1282-1285. doi:10.1016/j.transproceed.2022.02.061

Weiss A, Hendrickx R, Stensgaard E, Jellingsø M, Sommer MOA. Kidney Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to COVID-19. Transplantation. 2023;107(5):1136-1138. doi:10.1097/TP.0000000000004462

Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489

Mehta RB, Silveira FP. COVID-19 after two doses of mRNA vaccines in kidney transplant recipients. Am J Transplant. 2021;21(12):4102-4104. doi:10.1111/ajt.16778

Duarsa GWK, Sugianto R, Yusari IGAAA, et al. Predictor factor for worse outcomes in kidney transplant recipients infected with coronavirus disease 2019: A systematic review and meta-analysis. Transpl Immunol. 2023;76:101739. doi:10.1016/j.trim.2022.101739

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med. 2020 Apr 6;:]. Intensive Care Med. 2020;46(5):846-848. doi:10.1007/s00134-020-05991-x

Fisher AM, Schlauch D, Mulloy M, et al. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Clin Transplant. 2021;35(4):e14216. doi:10.1111/ctr.14216

Akalin E, Azzi Y, Bartash R, et al. COVID-19 and Kidney Transplantation. N Engl J Med. 2020;382(25):2475-2477. doi:10.1056/NEJMc2011117

Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant. 2020;20(7):1849-1858. doi:10.1111/ajt.15929

Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088. doi:10.1016/j.kint.2020.04.002

Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration [published correction appears in Nephrol Dial Transplant. 2021 Feb 24;:]. Nephrol Dial Transplant. 2020;35(11):1973-1983. doi:10.1093/ndt/gfaa261

Demir E, Uyar M, Parmaksiz E, et al. COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul. Transpl Infect Dis. 2020;22(5):e13371. doi:10.1111/tid.13371

Abadja F, Atemkeng S, Alamartine E, Berthoux F, Mariat C. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation. 2011;92(4):396-403. doi:10.1097/TP.0b013e3182247b5f

Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 [published correction appears in Virus Res. 2023 Jan 2;323:198952]. Virus Res. 2012;165(1):112-117. doi:10.1016/j.virusres.2012.02.002

Lee YC, Liu L, Yuan L, et al. Influenza vaccine effectiveness against hospitalized SARS-CoV-2 infection. Preprint. medRxiv. 2023;2023.10.27.23297682. Published 2023 Oct 31. doi:10.1101/2023.10.27.23297682

Vojdani A, Vojdani E, Melgar AL, Redd J. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. Front Immunol. 2022;13:1003094. Published 2022 Sep 23. doi:10.3389/fimmu.2022.1003094

Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?. Allergy. 2020;75(7):1815-1819. doi:10.1111/all.14345

Kolin DA, Kulm S, Christos PJ, Elemento O. Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank. PLoS One. 2020;15(11):e0241264. Published 2020 Nov 17. doi:10.1371/journal.pone.0241264

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

Ng JH, Hirsch JS, Hazzan A, et al. Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury. Am J Kidney Dis. 2021;77(2):204-215.e1. doi:10.1053/j.ajkd.2020.09.002

Moledina DG, Simonov M, Yamamoto Y, et al. The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. Am J Kidney Dis. 2021;77(4):490-499.e1. doi:10.1053/j.ajkd.2020.12.007

Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021;174(9):1330-1332. doi:10.7326/L21-0282

Alejo JL, Mitchell J, Chiang TP, et al. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [published correction appears in Transplantation. 2022 Feb 1;106(2):e177]. Transplantation. 2021;105(12):e280-e281. doi:10.1097/TP.0000000000003934

Downloads

Published

2024-02-14

How to Cite

Atılgan, K. G., Erinç Altınbaş, B., Ulusal Okyay, G., Ayerden Ebinç, F., Gök Oğuz, E., Şencan, İrfan, & Aylı, M. D. (2024). Prognosis and Risks for Renal Transplant Recipients During the COVID-19 Pandemic : Renal Transplant Recipients and COVID-19. Journal of European Internal Medicine Professionals, 2(1). https://doi.org/10.5281/zenodo.10654141

Issue

Section

Original Article

Categories